Before I start, don’t forget my deal of the day! Today back by popular demand I have the TradeKing deal. Also, don’t forget if you have to make any type of purchase from Amazon simply follow my link here, any purchase will help GekkoWire out and there are no extra charges to you, just a simple click on a link!!!!
Get $50 when you open a TradeKing account today. » Read more: Epicept Corporation (EPCT): Victim of FDA Politics? What all Cancer Company Investors Need to Know
Keryx Biopharmaceuticals (KERX) Update
Alright pharma investors time for the Kerx rundown, but before I start I would also like to let you that I will be doing what I call the “Deal of the Day.” This is where I partner with an affiliate to bring you a deal that you can’t get elsewhere, I have tons of great coupons at my fingertips, » Read more: Keryx Biopharmaceuticals (KERX) Update
Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
So a lot of investors have been wondering what will happen to cancer drugs that are in the Accelerated approval process because of the recent fiasco surrounding Avastin. For those that don’t know the story, Avastin is a drug for breast cancer that has had significant setbacks. The drug was approved under the FDA’s coveted Accelerated Approval Process. » Read more: Dr. Pazdur Speaks out on Cancer Trials and Accelerated Approvals
Keryx Biopharmaceuticals (KERX):
Keryx biopharmaceuticals said this morning that they have appointed Joseph Feczko to the company’s Board Of Directors. Mr. Feczko was the former Chief Medical Offer for Pfizer and was behind several of Pfizer massive successes. While at Pfizer he was involved with numerous efforts to push forward the drugs Viagra, Chantix and Celebrex. Mr. Feczko also worked their when Pfizer correctly stopped development of the torcetrapib cholesterol pill because of heart problems. The news is especially positive given that Mr. Feczko was directly responsible for key aspects of blockbuster drugs Chantix/Champix, Lyrica and Sutent. » Read more: Daily Pharma watch
Daily Pharma Watch
Today is the big day for Vivus, they will meet with an advisory panel to discuss their lead product Qnexa. I am expecting a decision to come out around 1:30-2:00 pm. The only real thing investors can do now is wait and see what happens, trading in the stock is halted, but should resume after the announcement or tomorrow. » Read more: Daily Pharma Watch
AEterna Zentaris (AEZS) and Keryx Pharmaceuticals (KERX):
This morning AEterna announced some very positive news out of the European Medicines Agency. The company said that they will not be forced to run an additional clinical trial of Perifosine in Colorectal Cancer patients to support a European Marketing Application. Keryx has licensed the rights to the drug in the U.S. for development and is currently conducting a Phase III clinical trial of the drug in multiple myeloma patients and colorectal cancer patients. » Read more: AEterna Zentaris (AEZS) and Keryx Pharmaceuticals (KERX): A Quick Update
Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
This post will actually be useful for several cancer companies out there so I have also included their names in the header, sorry for the ridiculously long title.
Alright ZIOPHARM investors, I have been asked what drugs garnered approval without an SPA designation by some readers. Last year, I had put together a post about how the Oncology Advisory Committee had voted in 2009, so I decided to repost that list and then include whether or not the company had received an SPA for the trial. This list focuses on cancer drugs only, so it is directly relevant to ZIOPHARM and other oncology companies with drugs in Phase III trials. » Read more: Special Protocol Assessment: The REAL DEAL Analysis: ZIOPHARM Oncology (ZIOP), Keryx Pharmaceuticals (KERX), AEterna Zentaris (AEZS), Delcath Systems (DCTH), Sunesis Pharmaceuticals (SNSS)
Keryx (KERX) Conference Call Rundown
So I took some time to listen to the two Keryx Investors Presentations held yesterday and today. I’ll give investors a brief rundown on the important information. Since most investors in the company are aware that they have 2 drugs in 3 Phase III SPA trials, I will stay away from drug data as I have already covered Perifosine in depth during this year’s ASCO. » Read more: Keryx (KERX) Conference Call Rundown
Regeneron Pharmaceuticals (REGN):
Regeneron announced results from their Phase III study in gout patients this morning. The company said that their drug Arcalyst reduced Gout flares by up to 80% (p-0.0001) in patients when given an 80 mg dose in one Phase III study. The company also reported data from a gout pain study in 225 patients with Arcalyst that showed that the drug did not significantly reduce the intensity of gout pain. » Read more: Daily Pharma Watch
Keryx’s Colon Cancer Trial, In Depth Rundown
I have been asked on numerous occasions what effect I think the wild type Kras gene mutation would have on the Phase III colon cancer study that the company is currently running. A study published back in 2008 in the NEJM (here) found that patients with a colorectal tumor bearing mutated K-ras did » Read more: Keryx’s Colon Cancer Trial, In Depth Rundown
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter